Condition: Depressive Disorder, Major · Treatment Outcome · Cognitive Dysfunction · Sponsor: Rigshospitalet, Denmark
The BrainDrugs-D study uses multimodal neuroimaging combined with self-report measures, clinical and molecular markers to identify clinically relevant predictors that can identify subtypes of major depressive disorder (MDD) and, in a naturalistic setting, predict treatment response to standard antidepressive treatment. The cohorts are followed in nationwide health registries.
This description comes directly from the study's public registry record.
Kristian HR Jensen, MD · +45 35456720 · kristian.reveles.jensen@nru.dk
Martin B Jørgensen, DMSc · +45 38647082 · Martin.Balslev.Joergensen@regionh.dk
Always discuss trial participation with your own doctor first.
| Neurobiology Research Unit, Rigshospitalet | Copenhagen, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05616559